Signaling Pathways in Gynecological Malignant Tumors

Dear Colleagues,

Gynecological malignant tumors are a diverse group of cancers that vary in their histology, etiology, and response to therapy. This group of malignancies includes ovarian, cervical, endometrial, and vaginal cancers, as well as cancers of the vulva and vagina. The development of gynecological malignant tumors is associated with the involvement of several signaling pathways, including:

1. PI3K/AKT/mTOR pathway: This pathway is involved in cell growth, proliferation, and survival. It is frequently activated in gynecological cancers, particularly ovarian and endometrial cancers.
2. Wnt/β-catenin pathway: This pathway is involved in cell differentiation, proliferation, and migration. It is frequently activated in cervical cancer, and plays a role in the development of cervical intraepithelial neoplasia (CIN).
3. Notch pathway: This pathway is involved in cell fate determination, differentiation, and apoptosis. It is frequently activated in ovarian cancer and plays a role in the development of chemoresistance.
4. Hedgehog pathway: This pathway is involved in embryonic development and tissue homeostasis. It is frequently activated in vulvar and vaginal cancers.
5. TGF-β pathway: This pathway is involved in cell differentiation, proliferation, and apoptosis. It is frequently altered in gynecological cancers, particularly cervical and endometrial cancers.

For the development of targeted therapies that can enhance patient outcomes, it is crucial to comprehend the function of these signaling pathways in the pathogenesis of gynecological cancers. For instance, everolimus and other drugs that target the PI3K/AKT/mTOR pathway have shown promise in the treatment of ovarian and endometrial cancer. Similarly, PRI-724 and other Wnt/β-catenin pathway inhibitors are being investigated for the treatment of cervical cancer.

The focus of this Special Issue will be on cutting-edge therapeutic signaling targets for gynecological cancerous tumors that improve our comprehension of how to target this intricate pathway in human cancers. The preference is given to manuscripts that promote inter- and/or transdisciplinary research by applying innovative conceptual thought to theoretical models, existing methodologies, and strategy applications. Authors with expertise in these pertinent study domains are encouraged to submit systematic reviews or methodological developments as well as original research studies for this Special Issue.

I look forward to receiving your contributions.

Dr. Iram Fatima
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• gynecological malignancies
• signaling pathways
• targeted therapy
• precision medicine
• combination therapy
• recurrence mechanisms
• cancer stem cell targeting